Sfoglia per Autore
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis
2021 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F.
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review
2021 Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F.
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
2021 Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M.
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials
2021 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F.
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence
2021 Rizzo A.; Rosellini M.; Marchetti A.; Mollica V.; Massari F.
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience
2021 Rizzo, Alessandro; Mollica, Veronica; Giunchi, Francesca; Dall'Olio, Filippo Gustavo; Rosellini, Matteo; Marchetti, Andrea; Franceschini, Tania; Schiavina, Riccardo; Brunocilla, Eugenio; Fiorentino, Michelangelo; Ardizzoni, Andrea; Massari, Francesco
Bone targeting agents in patients with metastatic prostate cancer: State of the art
2021 Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucci C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F.
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
2021 Rizzo A.; Santoni M.; Mollica V.; Logullo F.; Rosellini M.; Marchetti A.; Faloppi L.; Battelli N.; Massari F.
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials
2021 Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ricci, Angela Dalia; Fiorentino, Michelangelo; Battelli, Nicola; Santoni, Matteo; Massari, Francesco
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma
2021 Marchetti A.; Rosellini M.; Rizzo A.; Mollica V.; Battelli N.; Massari F.; Santoni M.
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt
2021 Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi R.; Massari F.
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
2021 Massari, Francesco; Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ardizzoni, Andrea; Santoni, Matteo
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
2022 Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F.
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
2022 Matteo Rosellini; Andrea Marchetti; Veronica Mollica; Alessandro Rizzo; Matteo Santoni; Francesco Massari
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
2022 Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.; Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F.
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
2022 Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M.
Current androgen receptor antagonists under investigation for resistant prostate cancer
2022 Nigro M.C.; Mollica V.; Marchetti A.; Cheng M.; Rosellini M.; Montironi R.; Cheng L.; Massari F.
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers
2022 Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fiorentino M.; Massari F.
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Mo...ntironi R.; Ardizzoni A.; Massari F. | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review | Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni ...M.; Ardizzoni A.; Massari F. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials | Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials | Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni... A.; Massari F. | 2021-01-01 | EUROPEAN UROLOGY FOCUS | - | 1.01 Articolo in rivista | - |
| Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence | Rizzo A.; Rosellini M.; Marchetti A.; Mollica V.; Massari F. | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience | Rizzo, Alessandro; Mollica, Veronica; Giunchi, Francesca; Dall'Olio, Filippo Gustavo; Rosellini, ...Matteo; Marchetti, Andrea; Franceschini, Tania; Schiavina, Riccardo; Brunocilla, Eugenio; Fiorentino, Michelangelo; Ardizzoni, Andrea; Massari, Francesco | 2021-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Bone targeting agents in patients with metastatic prostate cancer: State of the art | Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucc...i C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2021 [Bone Mets].pdf |
| Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study | Rizzo A.; Santoni M.; Mollica V.; Logullo F.; Rosellini M.; Marchetti A.; Faloppi L.; Battelli N....; Massari F. | 2021-01-01 | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | - | 1.01 Articolo in rivista | - |
| Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials | Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ricci, Angela Dalia; ...Fiorentino, Michelangelo; Battelli, Nicola; Santoni, Matteo; Massari, Francesco | 2021-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma | Marchetti A.; Rosellini M.; Rizzo A.; Mollica V.; Battelli N.; Massari F.; Santoni M. | 2021-01-01 | EXPERT OPINION ON PHARMACOTHERAPY | - | 1.01 Articolo in rivista | - |
| An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt | Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi... R.; Massari F. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-22-13519-v2.pdf |
| Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials | Massari, Francesco; Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; A...rdizzoni, Andrea; Santoni, Matteo | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis | Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F. | 2022-01-01 | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | - | 1.01 Articolo in rivista | - |
| Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma | Matteo Rosellini; Andrea Marchetti; Veronica Mollica; Alessandro Rizzo; Matteo Santoni; Francesco... Massari | 2022-01-01 | NATURE REVIEWS. UROLOGY | - | 1.01 Articolo in rivista | - |
| Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma | Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.;... Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F. | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy | Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M. | 2022-01-01 | CANCER MANAGEMENT AND RESEARCH | - | 1.01 Articolo in rivista | CMAR 2022 [Eli UC after first line].pdf |
| Current androgen receptor antagonists under investigation for resistant prostate cancer | Nigro M.C.; Mollica V.; Marchetti A.; Cheng M.; Rosellini M.; Montironi R.; Cheng L.; Massari F. | 2022-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers | Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fio...rentino M.; Massari F. | 2022-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
| Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer | Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile